Dapagliflozin/saxagliptin/metformin

Dapagliflozin/saxagliptin/metformin
Combination of
Dapagliflozin	SGLT-2 inhibitor
Saxagliptin	DPP‑4 inhibitor
Metformin	Anti-diabetic biguanide
Clinical data
Trade names	Qternmet XR, Qtrilmet
AHFS/Drugs.com	Professional Drug Facts
License data	US DailyMed: Qternmet;
Routes of; administration	By mouth
ATC code	A10BD25 (WHO) ;
Legal status
Legal status	US: ℞-only; EU: Rx-only;
Identifiers
CAS Number	2447636-43-1;
KEGG	D11711;

Dapagliflozin/saxagliptin/metformin, sold under the brand name Qternmet XR among others, is a fixed-dose combination anti-diabetic medication used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. It is a combination of dapagliflozin, saxagliptin, and metformin. It is taken by mouth. The drug is marketed by AstraZeneca.

The most common side effects include infections of the nose and throat, hypoglycaemia (low blood sugar) when used with a sulphonylurea and effects on the gut such as nausea (feeling sick), vomiting, diarrhoea, abdominal (tummy) pain and loss of appetite.

Dapagliflozin/saxagliptin/metformin was approved for medical use in the United States in May 2019, and in the European Union in November 2019. Its marketing authorisation was withdrawn in the European Union in August 2020, and its approval was withdrawn in the US in April 2021, in both cases at the request of AstraZeneca.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.